These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 36619616)

  • 41. Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future.
    Alzeibak R; Mishchenko TA; Shilyagina NY; Balalaeva IV; Vedunova MV; Krysko DV
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33431631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Research progress in inducing immunogenic cell death of tumor cells.
    Xie D; Wang Q; Wu G
    Front Immunol; 2022; 13():1017400. PubMed ID: 36466838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy.
    Catanzaro E; Feron O; Skirtach AG; Krysko DV
    Front Immunol; 2022; 13():925290. PubMed ID: 35844506
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenic Cell Death-Based Cancer Vaccines.
    Jin MZ; Wang XP
    Front Immunol; 2021; 12():697964. PubMed ID: 34135914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.
    Kuang X; Xiao J; Dai LX; Zhang LH; He BX
    Transl Cancer Res; 2019 Jun; 8(3):736-751. PubMed ID: 35116812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
    Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
    Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
    Roys A; Chang X; Liu Y; Xu X; Wu Y; Zuo D
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):679-688. PubMed ID: 31256210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers.
    Chiaravalli M; Spring A; Agostini A; Piro G; Carbone C; Tortora G
    Cells; 2022 Sep; 11(19):. PubMed ID: 36230995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanisms of immunogenic cell death and immune checkpoint blockade therapy.
    Lin RA; Lin JK; Lin SY
    Kaohsiung J Med Sci; 2021 Jun; 37(6):448-458. PubMed ID: 33636043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.
    Fois SS; Paliogiannis P; Zinellu A; Fois AG; Cossu A; Palmieri G
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435440
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomaterials That Induce Immunogenic Cell Death.
    Li D; Liu S; Ma Y; Liu S; Liu Y; Ding J
    Small Methods; 2023 May; 7(5):e2300204. PubMed ID: 37116170
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New horizons for uncommon mutations in non-small cell lung cancer:
    Olmedo ME; Cervera R; Cabezon-Gutierrez L; Lage Y; Corral de la Fuente E; Gómez Rueda A; Mielgo-Rubio X; Trujillo JC; Couñago F
    World J Clin Oncol; 2022 Apr; 13(4):276-286. PubMed ID: 35582653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.
    Workenhe ST; Mossman KL
    Mol Ther; 2014 Feb; 22(2):251-256. PubMed ID: 24048442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
    Bao X; Xie L
    J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
    Arbour KC; Riely GJ
    JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequency of actionable alterations in epidermal growth factor receptor
    Chiadini E; Canale M; Delmonte A; Dazzi C; Casanova C; Capelli L; Mariotti M; Papi M; Gamboni A; Puccetti M; Bravaccini S; Dubini A; Calistri D; Crinò L; Ulivi P
    J Thorac Dis; 2018 Aug; 10(8):4858-4864. PubMed ID: 30233859
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 59. Current Landscape of Targeted Therapy in Lung Cancer.
    Mayekar MK; Bivona TG
    Clin Pharmacol Ther; 2017 Nov; 102(5):757-764. PubMed ID: 28786099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review).
    Songjang W; Nensat C; Pongcharoen S; Jiraviriyakul A
    Biomed Rep; 2021 Oct; 15(4):86. PubMed ID: 34512974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.